Literature DB >> 30557531

Vitrectomy for Diabetic Macular Edema: Optical Coherence Tomography Criteria and Pathology of the Vitreomacular Interface.

Felix Hagenau1, Denise Vogt2, Jean Ziada2, Stefanie R Guenther2, Christos Haritoglou3, Armin Wolf2, Siegfried G Priglinger2, Ricarda G Schumann2.   

Abstract

PURPOSE: To correlate spectral-domain optical coherence tomography (SDOCT) criteria and clinical data with pathology of the vitreomacular interface (VMI) in eyes with diabetic macular edema (DME).
DESIGN: Retrospective cross-sectional study and laboratory investigation.
METHODS: We included specimens of 27 eyes of 26 patients with center-involved DME that underwent vitrectomy with peeling of the internal limiting membrane (ILM). Selection of specimens was consecutive and in retrospect using our register of the Vitreoretinal Pathology Unit. Clinical data and SDOCT examinations were correlated to immunocytochemistry and transmission electron microscopy. Classification of DME comprised sponge-like diffuse retinal thickening, cystoid macular edema, and serous retinal detachment. VMI was evaluated for presence of epiretinal membrane (ERM) and thickened vitreous cortex (tVC).
RESULTS: ERMs and tVC were found in all DME types. Diffuse DME showed tVC more often than cystoid DME. Hyalocytes, contractile myofibroblasts, glial cells, matrix metalloproteinases-2 and -9, and collagen type I, II, and III were positive tested irrespective of DME type. There were no significant cell fragments at the retinal side of the ILM. Visual acuity improved in the majority of cases and macular thickness decreased significantly during mean follow-up of 17 ± 10 months.
CONCLUSIONS: All eyes presented pathologic VMI changes irrespective of the OCT classification of DME type or presence of ERM. Composition of fibrocellular membranes at the VMI indicated remodeling of vitreous cortex and transdifferentiation of hyalocytes into myofibroblasts. Our findings might argue for an early surgical intervention in eyes with DME irrespective of the presence of traction formation imaged by SDOCT.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Year:  2018        PMID: 30557531     DOI: 10.1016/j.ajo.2018.12.004

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Factors associated with diabetic macular edema in patients with proliferative diabetic retinopathy.

Authors:  John R O'Fee; Joseph Juliano; Andrew A Moshfeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-22       Impact factor: 3.117

2.  Vitreomacular Interface Disorders in Proliferative Diabetic Retinopathy: An Optical Coherence Tomography Study.

Authors:  Aidi Lin; Honghe Xia; Anlin Zhang; Xinyu Liu; Haoyu Chen
Journal:  J Clin Med       Date:  2022-06-07       Impact factor: 4.964

3.  One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema.

Authors:  Thi Ha Chau Tran; Ali Erginay; Stephane Verdun; Eric Fourmaux; Jean-François Le Rouic; Joel Uzzan; Solange Milazzo; Stephanie Baillif; Laurent Kodjikian
Journal:  Clin Ophthalmol       Date:  2021-05-11

4.  FOVEA-SPARING VERSUS COMPLETE INTERNAL LIMITING MEMBRANE PEELING IN VITRECTOMY FOR VITREOMACULAR INTERFACE DISEASES: A Systematic Review and Meta-Analysis.

Authors:  Yuelin Wang; Xinyu Zhao; Wenfei Zhang; Jingyuan Yang; Youxin Chen
Journal:  Retina       Date:  2021-06-01       Impact factor: 4.256

5.  Involvement of Müller Glial Autoinduction of TGF-β in Diabetic Fibrovascular Proliferation Via Glial-Mesenchymal Transition.

Authors:  Di Wu; Atsuhiro Kanda; Ye Liu; Kousuke Noda; Miyuki Murata; Susumu Ishida
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-12-01       Impact factor: 4.799

6.  Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema.

Authors:  Solange Milazzo; Thi Ha Chau Tran; Stephane Verdun; Jean François Le Rouic; Joel Uzzan; Laurent Kodjikian; Ali Erginay
Journal:  Clin Ophthalmol       Date:  2022-03-07

7.  Change of Optical Coherence Tomography Morphology and Associated Structural Outcome in Diabetic Macular Edema after Ranibizumab Treatment.

Authors:  Nan-Ni Chen; Chien-Hsiung Lai; Chai-Yi Lee; Chien-Neng Kuo; Ching-Lung Chen; Jou-Chen Huang; Pei-Chen Wu; Pei-Lun Wu; Chau-Yin Chen
Journal:  J Pers Med       Date:  2022-04-11

8.  The association between different hypoglycemic regimens and postoperative diabetic macular edema after vitrectomy in the Japanese patients with proliferative diabetic retinopathy.

Authors:  Chunyan Lei; Yun Zhang; Meixia Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

9.  Hyperreflective Membrane at the Vitreoretinal Interface in Diabetic Macular Edema: A Finding in Ultra-High-Resolution Optical Coherence Tomography.

Authors:  Iori Wada; Shintaro Nakao; Mitsuru Arima; Keijiro Ishikawa; Muneo Yamaguchi; Yoshihiro Kaizu; Haruka Sekiryu; Kenichiro Mori; Kohei Kiyohara; Atsunobu Takeda; Tatsuro Ishibashi; SriniVas R Sadda; Koh-Hei Sonoda
Journal:  Transl Vis Sci Technol       Date:  2022-09-01       Impact factor: 3.048

10.  Aqueous humor analyses of diabetic macular edema patients with subretinal fluid.

Authors:  Jin-Woo Kwon; Byungjin Kim; Donghyun Jee; Yang Kyung Cho
Journal:  Sci Rep       Date:  2021-10-25       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.